Tricuspid Regurgitation
Conditions
Keywords
tricuspid, regurgitation, repair, outcomes
Brief summary
The TriCinch System™ is intended for percutaneous treatment of tricuspid regurgitation. It is a percutaneous catheter-based device designed for tricuspid valve repair in order to decrease effective cross-sectional area and relieve symptoms in patients with tricuspid valve regurgitation.
Detailed description
Implantation Procedure: Unlike the standard open chest, arrested heart approach, the 4TECH TriCinch System™ provides a percutaneous solution for tricuspid valve regurgitation treatment: this procedure is performed through deep sedation, while the heart is beating, without the need for respiratory assistance. The TriCinch System™ consists of a Delivery System that enables transcatheter placement of an implant that can be adjusted to correct Tricuspid valve regurgitation. The TriCinch Delivery System is inserted from the femoral vein to access the right atrium of the heart. At the end of the correction process, the TriCinch Delivery System and the venous introducer are removed and the procedure is concluded.
Interventions
DEVICETriCinch System
Percutaneous treatment of Tricuspid Regurgitation
Sponsors
4Tech Cardio Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Functional symptomatic tricuspid regurgitation (TR) 2+ to 4+ on a scale of 4+ (moderate to severe), with annular dilatation greater than 40mm. * Signed informed consent form prior to any study-related procedure. * Available and able to return to the study site for post-procedural follow-up examination * Eighteen (18) years of age or older.
Exclusion criteria
* Requirement for concomitant cardiac procedure (other than atrial fibrillation correction surgery, closure of PFO (Patent Foramen Ovale) or ASD (Atrial Septal Defect), or PTCA (percutaneous treatment of coronary artery) or CAD (coronary artery bypass surgery) from 1 to 3 months after or before other procedure. * Presence of any known life threatening (non-cardiac major or progressive disease), non-cardiac disease that will limit the subject's life expectancy to less than one year. * Cerebro-vascular event within the past 6 months. * History of mitral/tricuspid endocarditis within the last 12 months. * Organic tricuspid disease. * Contraindication or known allergy to device's components, aspirin, anti-coagulation therapy or contrast media that cannot be adequately premeditated. * Severe hypertension (SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg, measurement done by sphygmomanometer with stethoscope, allow the patient to sit for at least 5 minutes before beginning BP measurements). * Female patient is pregnant (urine HCG test result positive) or lactating. * Known alcohol or drug abuser. * Currently participating in the study of an investigational drug or device. * At heart team's judgement, patient IVC dimension is not adequate for device implantation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Performance: The reduction in degree of tricuspid regurgitation measured immediately after the procedure compared to baseline. | intraoperative | Ability to reduce tricuspid regurgitation by at least 1 degree immediately following implantation of the TriCinch device assessed by means of quantitative echocardiographic parameters. |
| Performance: The reduction in the degree of tricuspid regurgitation measured at time of discharge compared to baseline. | Time of discharge - 5 days | Ability to reduce tricuspid regurgitation by at least 1 degree immediately following implantation of the TriCinch device assessed by means of quantitative echocardiographic parameters. |
| Safety: The percentage of participants with Major Adverse Events within 30 days of the procedure. | Up to 30 days | Freedom from major adverse event: death, Q-wave myocardial infarction, cardiac tamponade, cardiac surgery for failed TriCinch implantation, stroke, or septicaemia. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Performance: Assessment in the degree of Tricuspid Regurgitation at 3 months compared to baseline. | 3 months | Ability to maintain Tricuspid Regurgitation with respect to baseline. |
| Performance: Assessment in the degree of Tricuspid Regurgitation at 6 months compared to baseline. | 6 months | Ability to maintain Tricuspid Regurgitation with respect to baseline. |
| Safety: The percentage of participants with Major Adverse Events up to 3 months of the procedure. | 3 months | Rate of device-related major adverse event (MAE). |
| Safety: The percentage of participants with Major Adverse Events within 6 months of the procedure. | 6 months | Rate of device-related Major Adverse Event (MAE). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life assessment | 6 months | Compare to baseline at 6 months |
Countries
France, Germany, Italy, Netherlands
Outcome results
None listed